<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of moderate and severe alcohol withdrawal syndromes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of moderate and severe alcohol withdrawal syndromes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of moderate and severe alcohol withdrawal syndromes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Hoffman, MD, FAACT, FEAPCCT, FRCP Edin</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald L Weinhouse, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Evan Schwarz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Grayzel, MD, FAAEM</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alcohol use disorder is a global health concern, ranking seventh among the leading causes of death and disability [<a href="#rid1">1</a>]. As such, most clinicians are forced to confront its complications in some of their patients. There are an estimated eight million alcohol-dependent people in the United States alone, and approximately 500,000 episodes of withdrawal severe enough to require pharmacologic treatment occur each year [<a href="#rid2">2</a>]. Expressed another way, between 2 and 7 percent of patients with significant alcohol use admitted for general medical care will develop severe alcohol withdrawal [<a href="#rid3">3</a>].</p><p>The inpatient management of syndromes associated with moderate and severe alcohol withdrawal is reviewed here. The ambulatory management of mild alcohol withdrawal, the initial diagnosis and treatment of alcohol use disorder, and specific conditions due to alcohol-related organ damage (eg, cirrhosis, pancreatitis) are discussed separately. (See  <a class="medical medical_review" href="/d/html/7801.html" rel="external">"Alcohol withdrawal: Ambulatory management"</a> and  <a class="medical medical_review" href="/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a> and  <a class="medical medical_review" href="/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a> and  <a class="medical medical_review" href="/d/html/7151.html" rel="external">"Hematologic complications of alcohol use"</a> and  <a class="medical medical_review" href="/d/html/14843.html" rel="external">"Screening for unhealthy use of alcohol and other drugs in primary care"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Overview</span><span class="headingEndMark"> — </span>It is not entirely clear why some individuals suffer from more severe withdrawal symptoms than others, but some evidence suggests that genetic predisposition may play a role [<a href="#rid4">4,5</a>]. Experiments in 1955 demonstrated that alcohol-naïve volunteers given continual alcohol for longer periods developed more severe withdrawal than those who drank for shorter periods [<a href="#rid6">6</a>]. These results imply that most people are vulnerable to the effects of the abrupt cessation of prolonged, sustained ethanol intake. Evidence is limited, and susceptibility to alcohol withdrawal varies among patients, but symptoms and signs of withdrawal can develop with abstinence after as little as a few weeks of consistent, heavy alcohol use. However, withdrawal usually does not occur in the general population because most people drink in an episodic fashion that does not lead to the sustained high blood concentrations of alcohol necessary to develop tolerance and withdrawal.</p><p>Symptoms of alcohol withdrawal occur because alcohol is a central nervous system depressant. Alcohol simultaneously enhances inhibitory tone (via modulation of gamma-aminobutyric acid [GABA] activity) and inhibits excitatory tone (via modulation of excitatory amino acid activity). In the patient with chronic, heavy alcohol use, only the constant presence of ethanol preserves homeostasis. Abrupt cessation unmasks the adaptive responses to chronic ethanol use, resulting in overactivity of the central nervous system.</p><p class="headingAnchor" id="H4"><span class="h2">Gamma-aminobutyric acid</span><span class="headingEndMark"> — </span>GABA is the major inhibitory neurotransmitter in the brain. Highly specific binding sites for ethanol are found on the GABA receptor complex [<a href="#rid7">7</a>]. Chronic ethanol use induces an insensitivity to GABA such that more inhibitor is required to maintain a constant inhibitory tone [<a href="#rid8">8</a>]. As alcohol tolerance develops, the individual retains arousal at alcohol concentrations that would normally produce lethargy or even coma in relatively alcohol-naïve individuals. Cessation of alcohol or a reduction from chronically elevated concentrations results in decreased inhibitory tone.</p><p class="headingAnchor" id="H5"><span class="h2">Excitatory amino acids</span><span class="headingEndMark"> — </span>Glutamate is one of the major excitatory amino acids. When glutamate binds to the N-methyl-D-aspartate (NMDA) receptor, calcium influx leads to neuronal excitation by binding to the glycine receptor on the NMDA complex. Ethanol inhibits glutamate-induced excitation [<a href="#rid9">9,10</a>]. Adaption occurs by increasing the number of glutamate receptors in an attempt to maintain a normal state of arousal. Cessation of alcohol or a reduction from chronically elevated concentrations results in unregulated excess excitation. Dopamine also appears to be involved in both alcohol dependency and the manifestations of withdrawal. Increases in dopamine during withdrawal likely contributes to hyperarousal [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H2075545196"><span class="h1">COMPLICATIONS OF ALCOHOL WITHDRAWAL</span></p><p class="headingAnchor" id="H6"><span class="h2">Minor withdrawal symptoms</span><span class="headingEndMark"> — </span>Minor withdrawal symptoms are due to central nervous system hyperactivity and include:</p><p class="bulletIndent1"><span class="glyph">●</span>Insomnia</p><p class="bulletIndent1"><span class="glyph">●</span>Tremulousness</p><p class="bulletIndent1"><span class="glyph">●</span>Mild anxiety</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal upset, anorexia</p><p class="bulletIndent1"><span class="glyph">●</span>Headache</p><p class="bulletIndent1"><span class="glyph">●</span>Diaphoresis</p><p class="bulletIndent1"><span class="glyph">●</span>Palpitations</p><p></p><p>Symptoms are usually present within six hours of the cessation of drinking and often develop while patients still have a significant blood alcohol concentration  (<a class="graphic graphic_table graphicRef75499" href="/d/graphic/75499.html" rel="external">table 1</a>) [<a href="#rid12">12</a>]. If withdrawal does not progress, these findings resolve within 24 to 48 hours. The specific minor withdrawal symptoms in a given patient are typically consistent from one episode to the next. The ambulatory management of mild alcohol withdrawal, including criteria to determine which patients are suitable for outpatient management, is discussed separately. (See  <a class="medical medical_review" href="/d/html/7801.html" rel="external">"Alcohol withdrawal: Ambulatory management"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Withdrawal seizures</span><span class="headingEndMark"> — </span>Withdrawal-associated seizures are generalized tonic-clonic convulsions that usually occur within 12 to 48 hours after the last alcoholic drink but reportedly sometimes occur after as few as two hours of abstinence  (<a class="graphic graphic_table graphicRef75499" href="/d/graphic/75499.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]. The seizures occur predominantly in patients with a long history of heavy alcohol use, as evidenced by their typical onset during the fourth and fifth decades of life.</p><p>Withdrawal seizures are usually singular or occur as a brief flurry of seizures over a short period. Recurrent or prolonged seizures or status epilepticus are not typical of withdrawal-associated seizures and should prompt an investigation into possible structural or infectious etiologies, generally guided by the findings of cranial computed tomography (CT), magnetic resonance imaging (MRI), and/or lumbar puncture. Benzodiazepines, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, and <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> are recommended in that order to treat status epilepticus while investigations proceed. Several studies have demonstrated that <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> is ineffective in the treatment of alcohol withdrawal seizures, and the drug should not be used for this purpose [<a href="#rid14">14-16</a>]. (See  <a class="medical medical_review" href="/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults"</a>.)</p><p>While some authors use other anticonvulsants such as <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, and <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> in the therapy of alcohol use disorder and withdrawal, the role of these medications in alcohol withdrawal-related seizures is incompletely evaluated and therefore cannot be recommended.</p><p>Although seemingly benign, alcohol withdrawal seizures left untreated progress to delirium tremens (DT) in nearly one-third of patients [<a href="#rid13">13</a>]. (See <a class="local">'Delirium tremens'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Alcoholic hallucinosis</span><span class="headingEndMark"> — </span>Despite a tendency to equate alcoholic hallucinosis with DT, the two terms are <strong>not</strong> synonymous. Alcoholic hallucinosis refers to hallucinations that develop within 12 to 24 hours of abstinence and typically resolve within 24 to 48 hours (which is the earliest point at which DT typically develops)  (<a class="graphic graphic_table graphicRef75499" href="/d/graphic/75499.html" rel="external">table 1</a>) [<a href="#rid17">17</a>]. Hallucinations are usually visual, although auditory and tactile phenomena are also described. Patients are aware that they are hallucinating and often very distressed. However, in contrast to DT, alcoholic hallucinosis is not associated with global clouding of the sensorium, only with specific hallucinations, and vital signs are usually normal. (See  <a class="medical medical_review" href="/d/html/5255.html" rel="external">"Approach to the patient with visual hallucinations", section on 'Alcohol and drug use or withdrawal'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Delirium tremens</span></p><p class="headingAnchor" id="H10"><span class="h3">Clinical manifestations of severe withdrawal and delirium tremens</span><span class="headingEndMark"> — </span>Approximately 5 percent of patients who undergo withdrawal from alcohol suffer from DT. DT is defined by hallucinations, disorientation, tachycardia, hypertension, hyperthermia, agitation, and diaphoresis in the setting of acute reduction or abstinence from alcohol. DT typically begins between 48 and 96 hours after the last drink and lasts one to five days  (<a class="graphic graphic_table graphicRef75499" href="/d/graphic/75499.html" rel="external">table 1</a>). DT and alcoholic hallucinosis are <strong>not</strong> synonymous, and symptoms that occur a few hours after the cessation of drinking, even if severe, are usually not manifestations of DT. Virtually all patients who develop DT experience some symptoms of minor alcohol withdrawal prior to the onset of DT. (See <a class="local">'Alcoholic hallucinosis'</a> above.)</p><p>Patients with DT have significantly elevated cardiac indices, oxygen delivery, and oxygen consumption [<a href="#rid18">18</a>]. Arterial pH rises due to hyperventilation, which may be a rebound effect related to the respiratory depressant properties of alcohol. Hyperventilation and consequent respiratory alkalosis in this setting result in a significant decrease in cerebral blood flow [<a href="#rid19">19</a>]. There is a correlation between the length of the preceding alcohol binge, the degree of clouding of the sensorium, and the size of the average decrease in cerebral hemispheric blood flow, although there is no association between blood flow parameters and hallucinations or tremors [<a href="#rid19">19</a>].</p><p>Severe alcohol withdrawal is often associated with fluid and electrolyte abnormalities, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypovolemia</strong> – Almost all patients in acute withdrawal are hypovolemic from diaphoresis, hyperthermia, vomiting, tachypnea, and decreased oral intake.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic acidosis</strong> – Metabolic acidosis may result from hypoperfusion, infection, alcoholic ketoacidosis, or <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a> (and other B vitamin) deficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypokalemia</strong> – Hypokalemia is common due to renal and extrarenal potassium losses, alterations in aldosterone concentrations, and changes in potassium distribution across the cell membrane [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypomagnesemia</strong> – Hypomagnesemia, which is common in patients with DT, predisposes them to dysrhythmias and seizures [<a href="#rid22">22</a>] and inhibits their response to <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypophosphatemia</strong> – Hypophosphatemia results from malnutrition, may be symptomatic, and, if severe, can contribute to cardiac failure and rhabdomyolysis.</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>Risk factors for the development of DT include [<a href="#rid3">3,23-25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Related to general patient factors and medical history:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age greater than 65</p><p class="bulletIndent2"><span class="glyph">•</span>Concurrent illness</p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid medical or surgical conditions (especially traumatic brain injury)</p><p class="bulletIndent2"><span class="glyph">•</span>Physiologic dependence on gamma-aminobutyric acid (GABA)-ergic agents (eg, benzodiazepine)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Related to past alcohol-related illness:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Long duration of heavy and regular alcohol consumption</p><p class="bulletIndent2"><span class="glyph">•</span>Numerous prior episodes of alcohol withdrawal</p><p class="bulletIndent2"><span class="glyph">•</span>History of alcohol withdrawal delirium or seizure</p><p class="bulletIndent2"><span class="glyph">•</span>History of DT</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Related to current illness:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant symptoms and signs of alcohol withdrawal in the presence of an elevated blood alcohol concentration</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A longer period since the last drink (ie, patients who present with alcohol withdrawal more than two days after their last drink are more likely to experience DT than those who present within two days)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Seizures during the current withdrawal period</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Marked autonomic hyperactivity on presentation</p><p></p><p>The best predictor for clinically significant alcohol withdrawal is a Prediction of Alcohol Withdrawal Severity Scale (PAWSS) score  (<a class="graphic graphic_table graphicRef119431" href="/d/graphic/119431.html" rel="external">table 2</a>) greater than or equal to 4 [<a href="#rid3">3,26,27</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Mortality</span><span class="headingEndMark"> — </span>With early identification and appropriate management, mortality from DT is less than 5 percent. This figure has fallen from the 37 percent mortality rate reported in the early 20<sup>th</sup> century, probably as a result of earlier diagnosis, improvements in supportive and pharmacologic therapies, and improved treatment of comorbid illnesses [<a href="#rid4">4,28-32</a>]. Death usually is due to dysrhythmia, complicating illnesses such as pneumonia, or failure to identify an underlying problem that led to the cessation of alcohol use, such as pancreatitis, hepatitis, or central nervous system injury or infection. Older age, pre-existing cardiopulmonary disease, core body temperature greater than 40ºC (104ºF), and coexisting liver disease are associated with a greater risk of mortality [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H13"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H14"><span class="h2">Excluding alternative diagnoses</span><span class="headingEndMark"> — </span>Alcohol withdrawal remains a clinical diagnosis. It may be necessary to perform extensive testing, including lumbar puncture and cranial computed tomography (CT) or magnetic resonance imaging (MRI), to exclude other diagnostic considerations with confidence. This is particularly true when the presentation includes altered mental status and fever. Conditions such as infection (eg, meningitis), trauma (eg, intracranial hemorrhage), metabolic derangements, drug overdose, hepatic failure, and gastrointestinal bleeding can mimic or coexist with alcohol withdrawal [<a href="#rid34">34</a>]. A premature diagnosis of alcohol withdrawal can lead to inappropriate use of sedatives, which can further delay accurate diagnosis [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Symptom control and supportive care</span><span class="headingEndMark"> — </span>Once comorbid illnesses have been excluded or adequately treated, the management of alcohol withdrawal is directed at alleviating symptoms and identifying and correcting metabolic derangements. Benzodiazepines are used to control psychomotor agitation and prevent progression to more severe withdrawal (see <a class="local">'Treatment of psychomotor agitation'</a> below). The appropriate use of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> as an adjunct therapy is discussed below. (See <a class="local">'Refractory delirium tremens, including use of phenobarbital'</a> below.)</p><p>Supportive care, including intravenous (IV) fluids, nutritional supplementation, and frequent clinical reassessment including vital signs, is important. Clinicians must avoid complacency when treating patients with alcohol withdrawal. (See <a class="local">'Disposition and monitoring'</a> below.)</p><p>Patients should be placed in a quiet, protective environment. Mechanical restraint may be temporarily necessary for patients suffering from delirium tremens (DT) to protect both the patient and caretakers. Clinicians should follow their facility's guidelines for documentation and implementation of physical restraints. Once adequate chemical sedation is achieved, physical restraints should be removed, as resistance against restraints can increase temperature, produce rhabdomyolysis, cause physical injury, and in extreme cases may provoke cardiac arrest. (See  <a class="medical medical_review" href="/d/html/139216.html" rel="external">"Restraint-related cardiac arrest: Pathogenesis, strategies for prevention, and management for hospital clinicians"</a>.)</p><p>Volume deficits can be calculated and replaced accordingly, or, if there are no contraindications, isotonic IV fluid can be infused rapidly until patients are clinically euvolemic. <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">Thiamine</a> and glucose should be administered in order to prevent or treat Wernicke encephalopathy [<a href="#rid36">36,37</a>]. Multivitamins containing or supplemented with folate should be given routinely, and deficiencies of glucose, potassium, magnesium, and phosphate should be corrected as needed. Initially (first day or two), treatment should be IV as gastrointestinal absorption is impaired in many patients with chronic, heavy alcohol use. The details of these supportive treatments are discussed separately. (See  <a class="medical medical_review" href="/d/html/4818.html" rel="external">"Wernicke encephalopathy", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/4840.html" rel="external">"Overview of the chronic neurologic complications of alcohol"</a> and  <a class="medical medical_review" href="/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults"</a> and  <a class="medical medical_review" href="/d/html/835.html" rel="external">"Hypophosphatemia: Evaluation and treatment"</a>.)</p><p>Some clinicians treat alcohol withdrawal patients with an IV infusion of a combination of <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a>, folate, and a multivitamin in isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> with 5% dextrose. The multivitamin makes the fluid appear yellow; thus, this treatment combination is sometimes referred to as a "banana bag." Use of this treatment has not been well studied with regard to clinical outcomes, and it may not meet the specific requirements for fluid, glucose, and other substrates of many patients with alcohol withdrawal. Thus, we do not recommend it.</p><p>During the early phases of moderate to severe alcohol withdrawal, patients are often given nothing by mouth (ie, kept "NPO") to prevent aspiration [<a href="#rid38">38</a>]. However, nutritional support is essential as patients with chronic, heavy alcohol use are frequently malnourished and have high metabolic needs due to their excited autonomic state. Initially, parenteral glucose supplementation is sufficient, but additional nutrition is needed for patients who remain unable to eat for more than a day or two. Patients considered at high risk for complications should be monitored in an intensive care unit (ICU). General indications for ICU admission are summarized in the following table  (<a class="graphic graphic_table graphicRef73377" href="/d/graphic/73377.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Treatment of psychomotor agitation</span></p><p class="headingAnchor" id="H17"><span class="h3">Drug selection</span><span class="headingEndMark"> — </span>Benzodiazepines are used to treat the psychomotor agitation most patients experience during withdrawal and to prevent progression from minor withdrawal symptoms to major ones [<a href="#rid29">29-31,34,38-42</a>]. The appropriate use of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> as an adjunct therapy is discussed below. (See <a class="local">'Refractory delirium tremens, including use of phenobarbital'</a> below.)</p><p><a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">Diazepam</a> (Valium), <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> (Ativan), and <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a> (Librium) are used most frequently to treat or prevent alcohol withdrawal, but other benzodiazepines may be used [<a href="#rid43">43</a>]. In general, long-acting benzodiazepines with active metabolites (eg, diazepam or chlordiazepoxide) are preferred because they seem to result in a smoother clinical course with lower chance of recurrent withdrawal or seizures. For most patients, we recommend a symptom-triggered approach to treatment with benzodiazepines; patients at greater risk of complications may be appropriate for a "front-loading" approach. (See <a class="local">'Symptom-triggered therapy'</a> below and <a class="local">'Front-loading therapy'</a> below.)</p><p>We prefer <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> (Ativan) or <a class="drug drug_general" data-topicid="9726" href="/d/drug information/9726.html" rel="external">oxazepam</a> (Serax) for the treatment of patients with advanced cirrhosis or acute alcoholic hepatitis. The shorter half-life of lorazepam and the absence of active metabolites with oxazepam may prevent prolonged effects if oversedation occurs. By contrast, <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a> has a relatively long half-life and may lead to oversedation in patients with severe liver disease. Treatment with agents available in parenteral form (eg, lorazepam, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>) may be necessary in patients who cannot receive oral medications.</p><p>Given the common occurrence of drug shortages, preferred agents may not always be available. A treatment algorithm for clinicians managing moderate or severe alcohol withdrawal without access to <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> is provided  (<a class="graphic graphic_algorithm graphicRef53322" href="/d/graphic/53322.html" rel="external">algorithm 1</a>).</p><p>Benzodiazepines exert their effect via stimulation of gamma-aminobutyric acid (GABA) receptors, causing a decrease in neuronal activity and relative sedation. (See <a class="local">'Gamma-aminobutyric acid'</a> above.)</p><p class="headingAnchor" id="H18"><span class="h3">Route</span><span class="headingEndMark"> — </span>All patients with seizures or DT require IV therapy with benzodiazepines. IV therapy is appropriate for the initial management of most patients with tremulousness from alcohol withdrawal because of guaranteed absorption and rapidity of onset. It is important to have IV access in all patients at risk of severe withdrawal.</p><p>Intramuscular administration of <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> should be avoided because of variable drug absorption. Oral formulations are preferred in most outpatient settings, for the prevention of withdrawal in asymptomatic patients known to be at risk, and for those with mild and minimal symptoms. (See <a class="local">'Prophylaxis'</a> below and  <a class="medical medical_review" href="/d/html/7801.html" rel="external">"Alcohol withdrawal: Ambulatory management"</a>.)</p><p>Following IV administration, patients should be converted to oral dosing as soon as possible based on their clinical response.</p><p class="headingAnchor" id="H19"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>Titration of medications should be based upon a given patient's risk factors for DT and for severe complications from the autonomic instability caused by DT. As an example, a patient younger than 45 years with no comorbid illnesses should be lightly sedated to a degree that ensures safety and comfort but does not obscure the neurologic examination. By contrast, an older patient with pre-existing cardiopulmonary disease may benefit from heavier sedation achieved more rapidly but must be closely monitored due to the greater risk imposed by the high systemic stress of major withdrawal or oversedation. The latter approach (rapidly performed, heavier sedation) is often referred to as "front-loading," as opposed to "symptom-triggered therapy."</p><p>Although no evidence-based data help to define which patients are most in need of a front-loading strategy, one simple assessment would be to determine if the patient is likely to be harmed by prolonged periods of hypertension and tachycardia (eg, frail, older adults; underlying cardiovascular disease) or by complications from prolonged physical restraint. All such patients likely require ICU admission. Suggested criteria for ICU admission are provided  (<a class="graphic graphic_table graphicRef73377" href="/d/graphic/73377.html" rel="external">table 3</a>). (See <a class="local">'Disposition and monitoring'</a> below.)</p><p>For front loading, a variety of dosing schedules can be used. We generally give <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> 5 to 10 mg IV every 5 to 10 minutes until the appropriate level of sedation is achieved. <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">Lorazepam</a> 2 to 4 mg IV every 15 to 20 minutes can also be used, but the longer interval required to wait to determine a peak effect of lorazepam almost contradicts the concept of front loading. In severe withdrawal, select patients may require massive doses (&gt;500 mg diazepam) to achieve initial control of symptoms and continued aggressive use of benzodiazepines thereafter (&gt;2000 mg diazepam over 48 hours). If diazepam is unavailable, we favor <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> for rapid symptom control.</p><p>While IV therapy is reasonable for patients not requiring front loading, equivalent doses of oral <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a> are on the order of 25 to 100 mg, which can be repeated hourly.</p><p>Fixed-schedule therapy, in which a benzodiazepine is given at fixed intervals even if symptoms are absent, is often administered despite evidence against this strategy [<a href="#rid44">44-47</a>]. A fixed-schedule strategy is most useful for preventing withdrawal in patients who are at risk but asymptomatic or minimally symptomatic. The only advantage of this strategy is for the provider, as frequent reassessment is not required. While we do not advocate this approach, if it is used, orders for a fixed dosing schedule must specify withholding the medication if the patient is sedated (ie, Richmond Agitation-Sedation Scale [RASS] &lt;0).</p><p class="headingAnchor" id="H20"><span class="h3">Symptom-triggered therapy</span><span class="headingEndMark"> — </span>A symptom-triggered approach is recommended for most patients to treat alcohol withdrawal when pharmacotherapy is indicated. It involves providing medication only when a patient has symptoms.</p><p>To use this approach, a regular systematic assessment should be made of the patient's status using a validated instrument, such as the Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA-Ar), a measure of withdrawal severity  (<a class="graphic graphic_table graphicRef64835" href="/d/graphic/64835.html" rel="external">table 4</a>) [<a href="#rid48">48</a>], or some equivalent assessment, such as the Severity of Ethanol Withdrawal Scale (SEWS) [<a href="#rid49">49</a>] or Brief Alcohol Withdrawal Scale (BAWS) [<a href="#rid50">50,51</a>]. A calculator to determine the CIWA-Ar score is provided (<a class="calc calc_professional" href="/d/html/13437.html" rel="external">calculator 1</a>). Evaluation intervals as frequent as every 10 to 15 minutes are appropriate for patients with more severe symptoms being treated with IV benzodiazepines. Once severe symptoms are controlled, hourly reassessment of such patients is reasonable. By contrast, an interval of four to six hours is reasonable for stable patients with mild symptoms receiving oral benzodiazepines.</p><p>When the score is elevated (any score of 8 or greater on the CIWA-Ar or 6 or greater on the SEWS), additional medication is given. For acute withdrawal, we give <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> 5 to 10 mg IV (<a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> 2 to 4 mg IV in patients with severe liver disease) or <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a> 25 to 100 mg orally (<a class="drug drug_general" data-topicid="9726" href="/d/drug information/9726.html" rel="external">oxazepam</a> 10 to 30 mg orally in patients with severe liver disease).</p><p>In some patients with severe alcohol withdrawal, including those who require tracheal intubation and mechanical ventilation, assessment scales such as the CIWA-Ar that rely upon patients being able to answer specific questions cannot be used effectively. In these patients, we suggest using a validated sedation scale such as the RASS  (<a class="graphic graphic_table graphicRef57874" href="/d/graphic/57874.html" rel="external">table 5</a>). We aim for a score of 0 to -2 when using the RASS to manage such patients. One advantage of the RASS score, which can be used in any clinical setting, is that it is a single-item scale that can be calculated in seconds. (See  <a class="medical medical_review" href="/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a>.)</p><p>Multiple randomized and observational studies support this simple concept of giving the patient the therapy they need only when they need it [<a href="#rid44">44-47,52</a>]. Taken collectively, these studies demonstrate that symptom-triggered therapy achieves equivalent or superior clinical endpoints while requiring lower total doses of sedatives and shorter periods of hospitalization.</p><p>In the landmark study of this approach, 101 patients admitted to an inpatient alcohol detoxification unit were randomly assigned to treatment with <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a> using a fixed schedule or a symptom-triggered therapy [<a href="#rid44">44</a>]. Patients in the symptom-triggered group required less medication (median 100 versus 425 mg) and a shorter treatment period (median 9 versus 68 hours) and had similar or better clinical outcomes.</p><p class="headingAnchor" id="H2098750421"><span class="h3">Front-loading therapy</span><span class="headingEndMark"> — </span>In contrast to symptom-triggered therapy, front-loading therapy consists of administering higher initial doses of benzodiazepine to prevent or achieve more rapid control of alcohol withdrawal symptoms. This approach is most appropriate for patients who are at greater risk of experiencing dangerous complications should they develop severe withdrawal. As one example, an older adult with a history of cardiovascular disease and DT would be good candidate. Dosing for front-loading therapy is described above. (See <a class="local">'Dosing'</a> above.)</p><p class="headingAnchor" id="H21"><span class="h2">Disposition and monitoring</span><span class="headingEndMark"> — </span>Patients being treated for moderate or severe alcohol withdrawal must be closely monitored, and many require admission to an ICU. A table of ICU admission criteria is provided  (<a class="graphic graphic_table graphicRef73377" href="/d/graphic/73377.html" rel="external">table 3</a>). Older patients with multiple medical comorbidities are at greater risk for DT and may not tolerate the systemic stress of major withdrawal. Standard monitoring includes continual assessment of vital signs, pulse oximetry, fluid and electrolyte status, and neurologic function. (See <a class="local">'Delirium tremens'</a> above.)</p><p class="headingAnchor" id="H22"><span class="h2">Refractory delirium tremens, including use of phenobarbital</span><span class="headingEndMark"> — </span>Some patients have refractory DT despite treatment with high-dose benzodiazepines, possibly because of low endogenous GABA concentrations or acquired conformational changes in the GABA receptor [<a href="#rid53">53,54</a>]. </p><p>Refractory DT is not clearly defined; the disorder is also referred to as "benzodiazepine-resistant alcohol withdrawal" [<a href="#rid55">55</a>]. The condition may be present if symptoms of severe withdrawal are not controlled adequately after the IV administration of more than 50 mg of <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> or 10 mg of <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> during the first hour of treatment, or 200 mg of diazepam or 40 mg of lorazepam during the initial three to four hours of treatment [<a href="#rid56">56</a>]. As discussed below, a few adjunctive treatments may be used to manage patients with refractory DT [<a href="#rid41">41,57,58</a>]. </p><p>In cases of refractory DT, as with any dangerous toxicologic disorder, we recommend obtaining assistance from a medical toxicologist or poison center. (See <a class="local">'Additional resources'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Barbiturates (</strong><a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a><strong>)</strong> – Barbiturates (specifically phenobarbital) can be very effective in these patients when given with a benzodiazepine [<a href="#rid56">56,59</a>]. Benzodiazepines (which increase the frequency of GABA chloride channel opening) and barbiturates (which increase the duration of channel opening) may work synergistically. </p><p></p><p class="bulletIndent1">We do <strong>not</strong> advocate the use of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> as monotherapy for patients in acute alcohol withdrawal. This is in large part due to the dearth of well-controlled, prospective studies and adequate safety data, as noted in 2023 systematic review and discussed further below [<a href="#rid60">60</a>]. Another systematic review and meta-analysis (eight studies total, two randomized trials, 1507 patients) concluded that phenobarbital monotherapy given in the emergency department was not superior to benzodiazepines in preventing ICU or hospital admission [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1">In patients thought to have refractory DT, we give <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> 130 to 260 mg IV, repeated every 15 to 20 minutes, until symptoms are controlled. Doses will vary depending on patient age, severity of withdrawal, and other clinical factors, with those at higher risk for adverse drug effects receiving smaller doses. Patients at higher risk of phenobarbital toxicity include older adults and patients with cardiovascular disease, chronic obstructive pulmonary disease, and volume depletion. Clinicians with limited experience using phenobarbital as an adjunct therapy for alcohol withdrawal are encouraged to seek assistance. (See <a class="local">'Additional resources'</a> below.)</p><p></p><p class="bulletIndent1">Studies of dosing in this setting are limited, but as a general rule, we do not exceed cumulative doses of 15 mg/kg in the first 24 hours. Once withdrawal symptoms are well controlled, maintenance dosing of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> is much less, typically around 130 to 260 mg IV <strong>total</strong> per day divided among two or three doses. This dosing continues for about three to five days. Importantly, tracheal intubation and mechanical ventilation are frequently necessary due to respiratory depression if phenobarbital is used in addition to benzodiazepine therapy.</p><p></p><p class="bulletIndent1">Evidence supporting the use of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> is limited [<a href="#rid58">58,60,62</a>]. In a randomized trial of 102 patients presenting to the emergency department with acute alcohol withdrawal, those treated with <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> and a single dose of phenobarbital had substantially lower ICU admission rates compared with those treated with lorazepam alone (8 versus 25 percent) [<a href="#rid59">59</a>]. However, the results of this study are limited by its small sample size, overlapping confidence intervals, and extensive uncontrolled use of other medications, including opioids, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, and neuroleptics [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent1">While several subsequent studies lend support for the combined use of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> and benzodiazepines [<a href="#rid64">64,65</a>] or phenobarbital alone [<a href="#rid66">66</a>], these findings are not universal [<a href="#rid67">67</a>]. The authors of a retrospective review of 86 ICU patients treated at a single hospital for alcohol withdrawal suggest that phenobarbital alone may be safe and effective treatment, but all patients in their study received benzodiazepines prior to ICU admission, and there was a high incidence of intubation from oversedation [<a href="#rid68">68</a>]. Many studies that support early administration or monotherapy with phenobarbital use an inadequate regimen of <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> as a comparator.</p><p></p><p class="bulletIndent1">Thus, while it is premature to recommend early administration of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> routinely, its use in patients who are both too ill for oral medications and receiving parenteral medications with limited active metabolites (<a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>) seems reasonable. However, because of the risks of cardiovascular and respiratory failure associated with phenobarbital, the absence of genuine comparative trials (ie, phenobarbital versus a benzodiazepine with active metabolites such as <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a> or <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>), and the proven benefits of symptom-triggered therapy with long-acting benzodiazepines, we continue to recommend against the use of phenobarbital as a single agent.</p><p></p><p class="bulletIndent1">Of note, prolonged use of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> induces hepatic enzymes, and clinicians should anticipate alterations in drug metabolism. In the context of substance use disorder, the most concerning interaction would be increased metabolism of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, possibly leading to subtherapeutic concentrations and a risk of opioid withdrawal [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> – Another reasonable alternative treatment for refractory DT is propofol, which can act to open chloride channels in the absence of GABA and may also antagonize the excitatory amino acids that are upregulated during alcohol withdrawal [<a href="#rid70">70,71</a>]. Importantly, tracheal intubation and mechanical ventilation are frequently necessary if propofol is used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">Dexmedetomidine</a> – Some preliminary evidence supports the use of dexmedetomidine as an adjunct in patients with refractory DT [<a href="#rid72">72</a>]. While this approach appears promising, we advise caution until well-performed, controlled trials of safety and efficacy are available.</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Alternative and contraindicated agents</span><span class="headingEndMark"> — </span>Drugs other than <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> and <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> have been used with benzodiazepines or, rarely, alone to treat alcohol withdrawal. These agents are less well studied than benzodiazepines and may mask the hemodynamic signs of withdrawal, which can precede seizures [<a href="#rid62">62</a>]. We believe they should <strong>not</strong> be used routinely in the treatment of moderate or severe alcohol withdrawal. Such drugs include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol</p><p class="bulletIndent1"><span class="glyph">●</span>Antipsychotics (eg, <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Anticonvulsants (eg, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Centrally acting alpha-2 agonists (eg, <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a>, <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beta blockers (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">Baclofen</a></p><p></p><p>All of these agents can reduce the frequency and intensity of minor withdrawal symptoms or prevent the craving for alcohol, but more data support the efficacy and safety of benzodiazepines in reducing the risk of seizures and DT. Many of these agents have an appropriate role in the outpatient management of minor alcohol withdrawal or of alcohol use disorder.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethanol</strong> – Ethanol should <strong>not</strong> be used as therapy in the setting of acute alcohol withdrawal. It is difficult to titrate, associated with many adverse metabolic and end-organ effects, and clearly inferior to benzodiazepines [<a href="#rid73">73</a>]. Of note, the metabolism and kinetics of ethanol have not been well studied in the critically ill.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antipsychotics</strong> – Phenothiazines and butyrophenones (including <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>) may lower the seizure threshold and should <strong>not</strong> be used routinely in the patient withdrawing from alcohol [<a href="#rid74">74</a>]. These drugs may also interfere with heat dissipation and do not exhibit cross-tolerance with ethanol.</p><p></p><p class="bulletIndent1">Treatment with antipsychotics would only be appropriate when a decompensated thought disorder (such as schizophrenia) coexists with ethanol withdrawal and any symptoms associated with ethanol withdrawal have been definitively treated with benzodiazepines. In our experience, such occurrences are rare, even in patients with known thought disorders.</p><p></p><p class="bulletIndent1">If a clinician determines that antipsychotic therapy is indicated, we recommend an electrocardiogram (ECG) to screen for QT prolongation (a contraindication to many antipsychotic medications) and the correction of electrolyte abnormalities (such as hypokalemia and hypomagnesemia, which are common in patients withdrawing from alcohol) <strong>before</strong> any medication is administered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticonvulsants</strong> – Sustained anticonvulsant therapy has no role in patients with isolated alcohol withdrawal seizures. The overwhelming majority of seizures from withdrawal are self-limited and do not require treatment with anticonvulsants. If status epilepticus ensues, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> or <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> may be used for short-term management in conjunction with benzodiazepines while an underlying cause is investigated. (See <a class="local">'Withdrawal seizures'</a> above.)</p><p></p><p class="bulletIndent1">While <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, and <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a> may have a role in the outpatient management of mild alcohol withdrawal, convincing evidence that these medications effectively treats patients with DT or other severe symptoms is lacking [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/7801.html" rel="external">"Alcohol withdrawal: Ambulatory management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Centrally acting alpha-2 agonists (eg, </strong><a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">Clonidine</a><strong>)</strong> ‒ Pending more convincing studies, we believe that centrally acting alpha-2 agonists (eg, <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a>, clonidine) should not be used as a primary treatment for acute severe alcohol withdrawal, and we do not recommend them as adjuncts for routine care.</p><p></p><p class="bulletIndent1">No controlled trials demonstrate that <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a> or <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a> prevent important outcomes, such as the development of seizures or DT. Despite this, clinicians increasingly report using these medications as adjunct therapy for alcohol withdrawal. While these drugs may reduce some symptoms of withdrawal as defined by CIWA-Ar or RASS scores [<a href="#rid76">76</a>], it is unclear whether their ability to reduce catecholaminergic findings is beneficial given that these agents are not cross-tolerant with alcohol and other GABA agonists. Dexmedetomidine seems to reduce benzodiazepine requirements [<a href="#rid77">77</a>], but this outcome is far from beneficial if benzodiazepines constitute definitive therapy. Furthermore, the use of dexmedetomidine is associated with increased cost and more episodes of bradycardia and hypotension [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers</strong> – Beta blockers may reduce minor symptoms of withdrawal, but they have not been shown to prevent the development of seizures or DT. We believe they should <strong>not</strong> be used for the treatment of acute severe alcohol withdrawal. However, patients with known cardiovascular disease should be given their maintenance medications after sedation and volume resuscitation, as sustained tachycardia and hypertension may contribute to cardiovascular morbidity, especially in older adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baclofen</strong> – <a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">Baclofen</a>, a selective agonist of the GABA-B receptor used to treat reversible spasticity, has been studied as a therapy for acute alcohol withdrawal, but its effectiveness in controlling severe symptoms remains unproven [<a href="#rid78">78-81</a>]. We believe baclofen should <strong>not</strong> be used for the treatment of acute severe alcohol withdrawal.</p><p></p><p class="headingAnchor" id="H24"><span class="h1">PROPHYLAXIS</span></p><p class="headingAnchor" id="H2826927121"><span class="h2">General admitted patients</span><span class="headingEndMark"> — </span>Patients with a history of seizures, delirium tremens (DT), or prolonged, heavy alcohol consumption who are minimally symptomatic or asymptomatic and are admitted to the hospital for other reasons can be prophylactically treated with oral <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a> or with <a class="drug drug_general" data-topicid="9726" href="/d/drug information/9726.html" rel="external">oxazepam</a> if severe liver disease is present. Should more severe symptoms develop, patients are treated for active withdrawal in standard fashion. (See <a class="local">'Management'</a> above.)</p><p>For prophylaxis, we give <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a> 25 to 100 mg every six hours for one day followed by 25 to 50 mg every six hours for an additional two days. A similar regimen can be used with <a class="drug drug_general" data-topicid="9726" href="/d/drug information/9726.html" rel="external">oxazepam</a> 10 to 30 mg. Monitoring is no different from patients in active withdrawal. Patients should be reassessed frequently and additional doses of medication given each hour if a score of 8 or greater is achieved on the Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA-Ar). If such scores are reached, prophylaxis has failed and patients should be treated for active withdrawal  (<a class="graphic graphic_table graphicRef64835" href="/d/graphic/64835.html" rel="external">table 4</a>) [<a href="#rid48">48</a>].</p><p>Asymptomatic or minimally symptomatic patients at lower risk for seizures or DT who are being admitted to the hospital for other reasons should be closely monitored and may be treated with oral <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a> 25 to 50 mg (or <a class="drug drug_general" data-topicid="9726" href="/d/drug information/9726.html" rel="external">oxazepam</a> 10 mg) every hour as needed when a score of 8 or greater is obtained on the CIWA-Ar.</p><p>After acute treatment, all patients should be screened for alcohol use disorder and should be considered at risk for recurrent episodes of withdrawal. In-hospital evaluation and long-term follow-up are recommended. (See  <a class="medical medical_review" href="/d/html/7810.html" rel="external">"Alcohol use disorder: Psychosocial management"</a>.)</p><p class="headingAnchor" id="H3963365047"><span class="h2">Patients with critical illness or on mechanical ventilation</span><span class="headingEndMark"> — </span>For patients requiring mechanical ventilation who are admitted to a critical care unit and who are thought to be at risk for severe alcohol withdrawal, we suggest providing intravenous (IV) sedation with a gamma-aminobutyric acid (GABA) agonist such as a benzodiazepine or <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>. <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">Dexmedetomidine</a> is not a good sedative choice for these patients. Should signs of withdrawal appear, we begin standard treatment with a benzodiazepine given IV. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a>.)</p><p>For patients on mechanical ventilation who do not require sedation but who are at risk for severe alcohol withdrawal, we suggest providing standard prophylaxis measures as described above, although the risk of precipitating an episode of intensive care unit (ICU) delirium must be weighed against the benefit of preventing withdrawal. (See <a class="local">'General admitted patients'</a> above.)</p><p>We recommend against the use of <a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">baclofen</a> as prophylactic therapy for critical care patients at risk of alcohol withdrawal. In a multicenter randomized trial, patients on mechanical ventilation and at risk for alcohol withdrawal (n = 314) were treated with high-dose baclofen or placebo plus standard care [<a href="#rid82">82</a>]. Although the trial reported a reduction in agitation events in the baclofen treatment group, events were largely transient and not clearly related to withdrawal. Furthermore, both the duration of intubation and ICU stay were significantly longer in the baclofen group. Mortality was also higher in the baclofen group, but the difference did not achieve statistical significance.</p><p class="headingAnchor" id="H25"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2023272451"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H452830201"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114306.html" rel="external">"Society guideline links: Alcohol use disorders and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a>.)</p><p class="headingAnchor" id="H182151126"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83392.html" rel="external">"Patient education: Alcohol withdrawal (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing, pathophysiology, and emergency management table</strong> – Susceptibility to alcohol withdrawal and timing vary, but symptoms and signs can develop within hours of abstinence following as little as a few weeks of consistent, significant alcohol use. A table summarizing the emergency management of moderate and severe alcohol withdrawal is provided  (<a class="graphic graphic_table graphicRef64745" href="/d/graphic/64745.html" rel="external">table 6</a>). (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dangerous diagnoses can mimic or coexist with alcohol withdrawal</strong> – Alcohol withdrawal remains a clinical diagnosis. It may be necessary to perform extensive testing (eg, lumbar puncture, computed tomography [CT], and/or magnetic resonance imaging [MRI]) to exclude other diagnoses as many patients with chronic, heavy alcohol use do not stop drinking spontaneously and present with overt withdrawal symptoms that may mask other disorders. Conditions such as infection, trauma, metabolic derangements, drug overdose, hepatic failure, and gastrointestinal bleeding can mimic or coexist with alcohol withdrawal. (See <a class="local">'Excluding alternative diagnoses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms of alcohol withdrawal</strong> – Alcohol withdrawal syndromes encompass symptoms ranging from mild tremulousness to life-threatening delirium tremens (DT). A table summarizing the timing of withdrawal symptoms is provided  (<a class="graphic graphic_table graphicRef75499" href="/d/graphic/75499.html" rel="external">table 1</a>). (See <a class="local">'Minor withdrawal symptoms'</a> above and <a class="local">'Withdrawal seizures'</a> above and <a class="local">'Alcoholic hallucinosis'</a> above and <a class="local">'Delirium tremens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delirium tremens</strong> – DT is a syndrome characterized by agitation, disorientation, hallucinations, and autonomic instability (tachycardia, hypertension, hyperthermia, and diaphoresis) in the setting of acute reduction or abstinence from alcohol. DT is associated with a mortality rate of up to 5 percent, but the rate can be substantially higher if the condition goes untreated. Alcoholic hallucinosis and DT are distinct clinical entities. Patients at risk and those who fail to respond appropriately to initial doses of sedatives should be monitored closely and treated aggressively  (<a class="graphic graphic_table graphicRef73377" href="/d/graphic/73377.html" rel="external">table 3</a>). (See <a class="local">'Delirium tremens'</a> above.)</p><p></p><p class="bulletIndent1">Risk factors for DT include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age greater than 65</p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid medical or surgical conditions (especially traumatic brain injury)</p><p class="bulletIndent2"><span class="glyph">•</span>Physiologic dependence on gamma-aminobutyric acid (GABA)-ergic agents (eg, benzodiazepine)</p><p class="bulletIndent2"><span class="glyph">•</span>Long duration of heavy and regular alcohol consumption</p><p class="bulletIndent2"><span class="glyph">•</span>Numerous prior episodes of alcohol withdrawal</p><p class="bulletIndent2"><span class="glyph">•</span>A history of alcohol withdrawal delirium or seizure or DT</p><p class="bulletIndent2"><span class="glyph">•</span>Significant symptoms and signs of alcohol withdrawal in the presence of elevated blood alcohol concentration</p><p class="bulletIndent2"><span class="glyph">•</span>Longer period since the last drink</p><p class="bulletIndent2"><span class="glyph">•</span>Seizures during the current withdrawal period</p><p class="bulletIndent2"><span class="glyph">•</span>Marked autonomic hyperactivity on presentation</p><p></p><p class="bulletIndent1">The best predictor for clinically significant alcohol withdrawal is a score of 4 or higher on the Prediction of Alcohol Withdrawal Severity Scale (PAWSS)  (<a class="graphic graphic_table graphicRef119431" href="/d/graphic/119431.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment and stabilization</strong> – Patients in alcohol withdrawal require medical treatment and observation. We suggest that patients who present with signs and symptoms of moderate or severe alcohol withdrawal be treated with benzodiazepines rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We give <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> 5 to 10 mg intravenously (IV), repeated every 5 to 10 minutes until symptoms are controlled. <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">Lorazepam</a> may also be used (2 to 4 mg IV, repeated every 15 to 20 minutes). The general goal of sedation is a calm but alert state. Patients at greater risk for adverse outcomes may need heavier sedation. IV benzodiazepines should be continued until it is clear that the patient is no longer delirious and at high risk for aspiration, and that absorption from the gut is reliable. (See <a class="local">'Treatment of psychomotor agitation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment tool for benzodiazepine dosing</strong> – Benzodiazepines should be dosed and administered using a validated assessment tool, such as the Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA-Ar)  (<a class="graphic graphic_table graphicRef64835" href="/d/graphic/64835.html" rel="external">table 4</a>). This requires formally assessing patients at regular intervals. Evaluation intervals as frequent as every 10 to 15 minutes are appropriate for patients with severe symptoms; an interval of four to six hours is reasonable for stable patients with mild symptoms. (See <a class="local">'Symptom-triggered therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and intensive care unit admission criteria</strong> – Patients with moderate or severe alcohol withdrawal need close monitoring, some in an intensive care unit (ICU) setting. Criteria for ICU admission are summarized in the following table  (<a class="graphic graphic_table graphicRef73377" href="/d/graphic/73377.html" rel="external">table 3</a>). (See <a class="local">'Disposition and monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory delirium tremens management</strong> – For DT refractory to aggressive treatment with high-dose benzodiazepines, we suggest treatment with <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> or <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients receiving these medications require ICU admission and will likely require mechanical ventilation  (<a class="graphic graphic_table graphicRef64745" href="/d/graphic/64745.html" rel="external">table 6</a>). (See <a class="local">'Refractory delirium tremens, including use of phenobarbital'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients at risk for withdrawal</strong> – Asymptomatic or minimally symptomatic patients at risk for alcohol withdrawal but admitted to the hospital for other reasons should be closely monitored and may be treated prophylactically with oral benzodiazepines. We use <a class="drug drug_general" data-topicid="9243" href="/d/drug information/9243.html" rel="external">chlordiazepoxide</a>. For patients on mechanical ventilation who are at risk for severe alcohol withdrawal, the preferred sedatives are GABA agonists, such as a benzodiazepine or <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>. (See <a class="local">'Prophylaxis'</a> above.)</p><p></p><p class="headingAnchor" id="H1137534309"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Stephen J Traub, MD, former section editor of the toxicology program, for 20 years of dedicated service.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018; 392:1015.</a></li><li><a class="nounderline abstract_t">Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348:1786.</a></li><li><a class="nounderline abstract_t">Wood E, Albarqouni L, Tkachuk S, et al. Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?: The Rational Clinical Examination Systematic Review. JAMA 2018; 320:825.</a></li><li><a class="nounderline abstract_t">Saitz R, O'Malley SS. Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med Clin North Am 1997; 81:881.</a></li><li><a class="nounderline abstract_t">Grzywacz A, Jasiewicz A, Małecka I, et al. Influence of DRD2 and ANKK1 polymorphisms on the manifestation of withdrawal syndrome symptoms in alcohol addiction. Pharmacol Rep 2012; 64:1126.</a></li><li><a class="nounderline abstract_t">ISBELL H, FRASER HF, WIKLER A, et al. An experimental study of the etiology of rum fits and delirium tremens. Q J Stud Alcohol 1955; 16:1.</a></li><li><a class="nounderline abstract_t">Mihic SJ, Ye Q, Wick MJ, et al. Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature 1997; 389:385.</a></li><li><a class="nounderline abstract_t">Morrow AL, Suzdak PD, Karanian JW, Paul SM. Chronic ethanol administration alters gamma-aminobutyric acid, pentobarbital and ethanol-mediated 36Cl- uptake in cerebral cortical synaptoneurosomes. J Pharmacol Exp Ther 1988; 246:158.</a></li><li><a class="nounderline abstract_t">Hoffman PL, Grant KA, Snell LD, et al. NMDA receptors: role in ethanol withdrawal seizures. Ann N Y Acad Sci 1992; 654:52.</a></li><li><a class="nounderline abstract_t">Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995; 152:332.</a></li><li><a class="nounderline abstract_t">Laine TP, Ahonen A, Torniainen P, et al. Dopamine transporters increase in human brain after alcohol withdrawal. Mol Psychiatry 1999; 4:189.</a></li><li><a class="nounderline abstract_t">Etherington JM. Emergency management of acute alcohol problems. Part 1: Uncomplicated withdrawal. Can Fam Physician 1996; 42:2186.</a></li><li><a class="nounderline abstract_t">Victor M, Brausch C. The role of abstinence in the genesis of alcoholic epilepsy. Epilepsia 1967; 8:1.</a></li><li><a class="nounderline abstract_t">Alldredge BK, Lowenstein DH, Simon RP. Placebo-controlled trial of intravenous diphenylhydantoin for short-term treatment of alcohol withdrawal seizures. Am J Med 1989; 87:645.</a></li><li><a class="nounderline abstract_t">Chance JF. Emergency department treatment of alcohol withdrawal seizures with phenytoin. Ann Emerg Med 1991; 20:520.</a></li><li><a class="nounderline abstract_t">Rathlev NK, D'Onofrio G, Fish SS, et al. The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. Ann Emerg Med 1994; 23:513.</a></li><li><a class="nounderline abstract_t">VICTOR M, ADAMS RD. The effect of alcohol on the nervous system. Res Publ Assoc Res Nerv Ment Dis 1953; 32:526.</a></li><li><a class="nounderline abstract_t">Abraham E, Shoemaker WC, McCartney SF. Cardiorespiratory patterns in severe delirium tremens. Arch Intern Med 1985; 145:1057.</a></li><li><a class="nounderline abstract_t">Berglund M, Risberg J. Regional cerebral blood flow during alcohol withdrawal related to consumption and clinical symptomatology. Acta Neurol Scand Suppl 1977; 64:480.</a></li><li><a class="nounderline abstract_t">Elisaf M, Liberopoulos E, Bairaktari E, Siamopoulos K. Hypokalaemia in alcoholic patients. Drug Alcohol Rev 2002; 21:73.</a></li><li><a class="nounderline abstract_t">Wadstein J, Skude G. Does hypokalaemia precede delirium tremens? Lancet 1978; 2:549.</a></li><li><a class="nounderline abstract_t">Victor M. The role of hypomagnesemia and respiratory alkalosis in the genesis of alcohol-withdrawal symptoms. Ann N Y Acad Sci 1973; 215:235.</a></li><li><a class="nounderline abstract_t">Ferguson JA, Suelzer CJ, Eckert GJ, et al. Risk factors for delirium tremens development. J Gen Intern Med 1996; 11:410.</a></li><li><a class="nounderline abstract_t">Cushman P Jr. Delirium tremens. Update on an old disorder. Postgrad Med 1987; 82:117.</a></li><li><a class="nounderline abstract_t">Schuckit MA, Tipp JE, Reich T, et al. The histories of withdrawal convulsions and delirium tremens in 1648 alcohol dependent subjects. Addiction 1995; 90:1335.</a></li><li><a class="nounderline abstract_t">Maldonado JR, Sher Y, Ashouri JF, et al. The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol 2014; 48:375.</a></li><li><a class="nounderline abstract_t">Maldonado JR, Sher Y, Das S, et al. Prospective Validation Study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) in Medically Ill Inpatients: A New Scale for the Prediction of Complicated Alcohol Withdrawal Syndrome. Alcohol Alcohol 2015; 50:509.</a></li><li><a class="nounderline abstract_t">Turner RC, Lichstein PR, Peden JG Jr, et al. Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment. J Gen Intern Med 1989; 4:432.</a></li><li><a class="nounderline abstract_t">DeBellis R, Smith BS, Choi S, Malloy M. Management of delirium tremens. J Intensive Care Med 2005; 20:164.</a></li><li><a class="nounderline abstract_t">Pristach CA, Smith CM, Whitney RB. Alcohol withdrawal syndromes - prediction from detailed medical and drinking histories. Drug Alcohol Depend 1983; 11:177.</a></li><li><a class="nounderline abstract_t">Boston, LN. Alcohol withdrawal. Lancet 1908; 1:18.</a></li><li><a class="nounderline abstract_t">Yost DA. Alcohol withdrawal syndrome. Am Fam Physician 1996; 54:657.</a></li><li><a class="nounderline abstract_t">TAVEL ME, DAVIDSON W, BATTERTON TD. A critical analysis of mortality associated with delirium tremens. Review of 39 fatalities in a 9-year period. Am J Med Sci 1961; 242:18.</a></li><li><a class="nounderline abstract_t">Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 2004; 164:1405.</a></li><li><a class="nounderline abstract_t">Hecksel KA, Bostwick JM, Jaeger TM, Cha SS. Inappropriate use of symptom-triggered therapy for alcohol withdrawal in the general hospital. Mayo Clin Proc 2008; 83:274.</a></li><li><a class="nounderline abstract_t">Hack JB, Hoffman RS. Thiamine before glucose to prevent Wernicke encephalopathy: examining the conventional wisdom. JAMA 1998; 279:583.</a></li><li><a class="nounderline abstract_t">Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. JAMA 1995; 274:562.</a></li><li><a class="nounderline abstract_t">Hoffman RS, Goldfrank LR. Ethanol-associated metabolic disorders. Emerg Med Clin North Am 1989; 7:943.</a></li><li><a class="nounderline abstract_t">Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010; :CD005063.</a></li><li><a class="nounderline abstract_t">Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev 2011; :CD008537.</a></li><li><a class="nounderline abstract_t">Schmidt KJ, Doshi MR, Holzhausen JM, et al. Treatment of Severe Alcohol Withdrawal. Ann Pharmacother 2016; 50:389.</a></li><li><a class="nounderline abstract_t">Bahji A, Bach P, Danilewitz M, et al. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Addiction 2022; 117:2591.</a></li><li><a class="nounderline abstract_t">Bird RD, Makela EH. Alcohol withdrawal: what is the benzodiazepine of choice? Ann Pharmacother 1994; 28:67.</a></li><li><a class="nounderline abstract_t">Saitz R, Mayo-Smith MF, Roberts MS, et al. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA 1994; 272:519.</a></li><li><a class="nounderline abstract_t">Jaeger TM, Lohr RH, Pankratz VS. Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients. Mayo Clin Proc 2001; 76:695.</a></li><li><a class="nounderline abstract_t">Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 2002; 162:1117.</a></li><li><a class="nounderline abstract_t">Cassidy EM, O'Sullivan I, Bradshaw P, et al. Symptom-triggered benzodiazepine therapy for alcohol withdrawal syndrome in the emergency department: a comparison with the standard fixed dose benzodiazepine regimen. Emerg Med J 2012; 29:802.</a></li><li><a class="nounderline abstract_t">Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84:1353.</a></li><li><a class="nounderline abstract_t">Beresford TP, Ronan PJ, Taub J, et al. Working Toward a Gold Standard: The Severity of Ethanol Withdrawal Scale (SEWS) Versus the Clinical Institute Withdrawal Assessment Alcohol Scale (CIWA-Ar). Alcohol Alcohol 2023; 58:324.</a></li><li><a class="nounderline abstract_t">Rastegar DA, Applewhite D, Alvanzo AAH, et al. Development and implementation of an alcohol withdrawal protocol using a 5-item scale, the Brief Alcohol Withdrawal Scale (BAWS). Subst Abus 2017; 38:394.</a></li><li><a class="nounderline abstract_t">Lindner BK, Gilmore VT, Kruer RM, et al. Evaluation of the Brief Alcohol Withdrawal Scale Protocol at an Academic Medical Center. J Addict Med 2019; 13:379.</a></li><li><a class="nounderline abstract_t">Spies CD, Otter HE, Hüske B, et al. Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU. Intensive Care Med 2003; 29:2230.</a></li><li><a class="nounderline abstract_t">Cagetti E, Liang J, Spigelman I, Olsen RW. Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABAA receptors. Mol Pharmacol 2003; 63:53.</a></li><li><a class="nounderline abstract_t">Nolop KB, Natow A. Unprecedented sedative requirements during delirium tremens. Crit Care Med 1985; 13:246.</a></li><li><a class="nounderline abstract_t">Langlois H, Cormier M, Villeneuve E, et al. Benzodiazepine resistant alcohol withdrawal: What is the clinician's preferred definition? CJEM 2020; 22:165.</a></li><li><a class="nounderline abstract_t">Hack JB, Hoffmann RS, Nelson LS. Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early? J Med Toxicol 2006; 2:55.</a></li><li><a class="nounderline abstract_t">Mo Y, Thomas MC, Laskey CS, et al. Current Practice Patterns in the Management Of Alcohol Withdrawal Syndrome. P T 2018; 43:158.</a></li><li><a class="nounderline abstract_t">Lindsay DL, Freedman K, Jarvis M, et al. Executive Summary of the American Society of Addiction Medicine (ASAM) Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med 2020; 14:376.</a></li><li><a class="nounderline abstract_t">Rosenson J, Clements C, Simon B, et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. J Emerg Med 2013; 44:592.</a></li><li><a class="nounderline abstract_t">Umar Z, Haseeb Ul Rasool M, Muhammad S, et al. Phenobarbital and Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis. Cureus 2023; 15:e33695.</a></li><li><a class="nounderline abstract_t">Lee CM, Dillon DG, Tahir PM, Murphy CE 4th. Phenobarbital treatment of alcohol withdrawal in the emergency department: A systematic review and meta-analysis. Acad Emerg Med 2023.</a></li><li><a class="nounderline abstract_t">Strayer RJ, Friedman BW, Haroz R, et al. Emergency Department Management of Patients With Alcohol Intoxication, Alcohol Withdrawal, and Alcohol Use Disorder: A White Paper Prepared for the American Academy of Emergency Medicine. J Emerg Med 2023; 64:517.</a></li><li><a class="nounderline abstract_t">Riggan MA, Hayman K, Chen BC, Hoffman RS. Regarding "Phenobarbital for Acute Alcohol Withdrawal: A Prospective Randomized Double-Blind Placebo-Controlled Study". J Emerg Med 2016; 50:895.</a></li><li><a class="nounderline abstract_t">Nguyen TA, Lam SW. Phenobarbital and symptom-triggered lorazepam versus lorazepam alone for severe alcohol withdrawal in the intensive care unit. Alcohol 2020; 82:23.</a></li><li><a class="nounderline abstract_t">Ibarra F Jr. Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal. Am J Emerg Med 2020; 38:178.</a></li><li><a class="nounderline abstract_t">Nejad S, Nisavic M, Larentzakis A, et al. Phenobarbital for Acute Alcohol Withdrawal Management in Surgical Trauma Patients-A Retrospective Comparison Study. Psychosomatics 2020; 61:327.</a></li><li><a class="nounderline abstract_t">Sullivan SM, Dewey BN, Jarrell DH, et al. Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the ED. Am J Emerg Med 2019; 37:1313.</a></li><li><a class="nounderline abstract_t">Oks M, Cleven KL, Healy L, et al. The Safety and Utility of Phenobarbital Use for the Treatment of Severe Alcohol Withdrawal Syndrome in the Medical Intensive Care Unit. J Intensive Care Med 2020; 35:844.</a></li><li><a class="nounderline abstract_t">Terasaki D, Kulick B, Calcaterra S, Ray L. Phenobarbital for alcohol withdrawal in the context of the opioid epidemic: a neglected caveat. Addiction 2023; 118:1198.</a></li><li><a class="nounderline abstract_t">McCowan C, Marik P. Refractory delirium tremens treated with propofol: a case series. Crit Care Med 2000; 28:1781.</a></li><li><a class="nounderline abstract_t">Brotherton AL, Hamilton EP, Kloss HG, Hammond DA. Propofol for Treatment of Refractory Alcohol Withdrawal Syndrome: A Review of the Literature. Pharmacotherapy 2016; 36:433.</a></li><li><a class="nounderline abstract_t">Tolonen J, Rossinen J, Alho H, Harjola VP. Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. Eur J Emerg Med 2013; 20:425.</a></li><li><a class="nounderline abstract_t">Hodges B, Mazur JE. Intravenous ethanol for the treatment of alcohol withdrawal syndrome in critically ill patients. Pharmacotherapy 2004; 24:1578.</a></li><li><a class="nounderline abstract_t">Blum K, Eubanks JD, Wallace JE, Hamilton H. Enhancement of alcohol withdrawal convulsions in mice by haloperidol. Clin Toxicol 1976; 9:427.</a></li><li><a class="nounderline abstract_t">Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 2010; :CD005064.</a></li><li><a class="nounderline abstract_t">Woods AD, Giometti R, Weeks SM. The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review. JBI Database System Rev Implement Rep 2015; 13:224.</a></li><li><a class="nounderline abstract_t">Crispo AL, Daley MJ, Pepin JL, et al. Comparison of clinical outcomes in nonintubated patients with severe alcohol withdrawal syndrome treated with continuous-infusion sedatives: dexmedetomidine versus benzodiazepines. Pharmacotherapy 2014; 34:910.</a></li><li><a class="nounderline abstract_t">Colombo G, Serra S, Brunetti G, et al. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend 2003; 70:105.</a></li><li><a class="nounderline abstract_t">Addolorato G, Caputo F, Capristo E, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med 2002; 112:226.</a></li><li><a class="nounderline abstract_t">Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119:276.e13.</a></li><li><a class="nounderline abstract_t">Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2017; 8:CD008502.</a></li><li><a class="nounderline abstract_t">Vourc'h M, Garret C, Gacouin A, et al. Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA 2021; 325:732.</a></li></ol></div><div id="topicVersionRevision">Topic 323 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30146330" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12724485" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of drug and alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30167704" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?: The Rational Clinical Examination Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222259" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pharmacotherapies for alcohol abuse. Withdrawal and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238469" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Influence of DRD2 and ANKK1 polymorphisms on the manifestation of withdrawal syndrome symptoms in alcohol addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14372008" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An experimental study of the etiology of rum fits and delirium tremens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311780" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2839659" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic ethanol administration alters gamma-aminobutyric acid, pentobarbital and ethanol-mediated 36Cl- uptake in cerebral cortical synaptoneurosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1321581" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : NMDA receptors: role in ethanol withdrawal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864257" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The glutamatergic basis of human alcoholism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10208452" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dopamine transporters increase in human brain after alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8939320" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Emergency management of acute alcohol problems. Part 1: Uncomplicated withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4961509" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The role of abstinence in the genesis of alcoholic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2686433" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Placebo-controlled trial of intravenous diphenylhydantoin for short-term treatment of alcohol withdrawal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024792" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Emergency department treatment of alcohol withdrawal seizures with phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8135426" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13134661" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The effect of alcohol on the nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4004431" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cardiorespiratory patterns in severe delirium tremens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/268883" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Regional cerebral blood flow during alcohol withdrawal related to consumption and clinical symptomatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12189007" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hypokalaemia in alcoholic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/79917" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Does hypokalaemia precede delirium tremens?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4513676" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The role of hypomagnesemia and respiratory alkalosis in the genesis of alcohol-withdrawal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8842933" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk factors for delirium tremens development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2890144" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Delirium tremens. Update on an old disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8616462" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The histories of withdrawal convulsions and delirium tremens in 1648 alcohol dependent subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657098" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999438" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prospective Validation Study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) in Medically Ill Inpatients: A New Scale for the Prediction of Complicated Alcohol Withdrawal Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2677272" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888905" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Management of delirium tremens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6861616" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Alcohol withdrawal syndromes - prediction from detailed medical and drinking histories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Alcohol withdrawal</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8701843" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Alcohol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13775521" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A critical analysis of mortality associated with delirium tremens. Review of 39 fatalities in a 9-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249349" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Management of alcohol withdrawal delirium. An evidence-based practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18315992" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inappropriate use of symptom-triggered therapy for alcohol withdrawal in the general hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486750" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Thiamine before glucose to prevent Wernicke encephalopathy: examining the conventional wisdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629986" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2680473" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Ethanol-associated metabolic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20238336" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Benzodiazepines for alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21678378" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26861990" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment of Severe Alcohol Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35194860" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8123967" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Alcohol withdrawal: what is the benzodiazepine of choice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8046805" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11444401" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020181" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22011975" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Symptom-triggered benzodiazepine therapy for alcohol withdrawal syndrome in the emergency department: a comparison with the standard fixed dose benzodiazepine regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2597811" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36935201" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Working Toward a Gold Standard: The Severity of Ethanol Withdrawal Scale (SEWS) Versus the Clinical Institute Withdrawal Assessment Alcohol Scale (CIWA-Ar).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28699845" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Development and implementation of an alcohol withdrawal protocol using a 5-item scale, the Brief Alcohol Withdrawal Scale (BAWS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30741834" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evaluation of the Brief Alcohol Withdrawal Scale Protocol at an Academic Medical Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557857" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488536" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABAA receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3979072" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Unprecedented sedative requirements during delirium tremens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31645232" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Benzodiazepine resistant alcohol withdrawal: What is the clinician's preferred definition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18072114" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29491698" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Current Practice Patterns in the Management Of Alcohol Withdrawal Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32909985" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Executive Summary of the American Society of Addiction Medicine (ASAM) Clinical Practice Guideline on Alcohol Withdrawal Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22999778" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36788902" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Phenobarbital and Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37923363" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Phenobarbital treatment of alcohol withdrawal in the emergency department: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36997435" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Emergency Department Management of Patients With Alcohol Intoxication, Alcohol Withdrawal, and Alcohol Use Disorder: A White Paper Prepared for the American Academy of Emergency Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27221017" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Regarding "Phenobarbital for Acute Alcohol Withdrawal: A Prospective Randomized Double-Blind Placebo-Controlled Study".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31326601" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Phenobarbital and symptom-triggered lorazepam versus lorazepam alone for severe alcohol withdrawal in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30744913" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32199629" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Phenobarbital for Acute Alcohol Withdrawal Management in Surgical Trauma Patients-A Retrospective Comparison Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30414743" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the ED.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925291" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The Safety and Utility of Phenobarbital Use for the Treatment of Severe Alcohol Withdrawal Syndrome in the Medical Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36967706" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Phenobarbital for alcohol withdrawal in the context of the opioid epidemic: a neglected caveat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890619" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Refractory delirium tremens treated with propofol: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26893017" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Propofol for Treatment of Refractory Alcohol Withdrawal Syndrome: A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247391" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15537562" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intravenous ethanol for the treatment of alcohol withdrawal syndrome in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/986285" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Enhancement of alcohol withdrawal convulsions in mice by haloperidol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20238337" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Anticonvulsants for alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26447017" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24898418" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparison of clinical outcomes in nonintubated patients with severe alcohol withdrawal syndrome treated with continuous-infusion sedatives: dexmedetomidine versus benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681531" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11893350" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Rapid suppression of alcohol withdrawal syndrome by baclofen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490478" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28822350" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Baclofen for alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33620407" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
